Sunshine Biopharma Inc. (SBFM) Gross margin 2019–2025
Sunshine Biopharma Inc. (SBFM) gross margin by fiscal year — reported gross profit divided by reported revenue.
33.8%FY2025 · since FY2019: 47.7% → 33.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 33.8% | +3.2 pp |
| FY2024 | 30.6% | -4.0 pp |
| FY2023 | 34.6% | -4.4 pp |
| FY2022 | 39.0% | -9.4 pp |
| FY2021 | 48.4% | -15.4 pp |
| FY2020 | 63.8% | +16.1 pp |
| FY2019 | 47.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SBFM financial trends
SBFM RevenueSBFM Net incomeSBFM Net marginSBFM Gross profitSBFM Operating incomeSBFM Operating marginSBFM Operating cash flowSBFM Free cash flowSBFM Capital expendituresSBFM Return on equitySBFM Stock buybacksSBFM Dividends paidSBFM Total assetsSBFM Total liabilitiesSBFM Shareholders’ equitySBFM overview →